ADVERTISEMENT
site_logo
  • Campus
  • Happening
  • Opinion
  • People
  • News
  • #BeInspired
  • Careers
  • 40 under 40
  • Exams
  • What The FAQ
  • Videos
    • Straight Up
    • Odisha Literary Festival 2020
    • Campus Convo
    • Careers After Corona
    • Express Expressions
    • Q&A With Prabhu Chawla
    • ThinkEdu Awards 2020
  • edex_worksEDEXWORKS
ADVERTISEMENT

Published: 02nd January 2021     

Lymphoma drug outperforms Remdesivir against COVID virus

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate drug is a promising candidate for COVID-19 patients

Edex Live
Edex Live
f_icon t_icon i_icon l_icon koo_icon whatsapp_icon email_icon

Share Via Email

drugs-medicine-capsule

Image for representational purpose only| Pic: Shutterstock

A chemotherapy medication originally developed to treat lymphoma has outperformed the popular remdesivir drug against SARS-CoV-2 in lab settings, and could potentially be repurposed to treat Covid-19, say researchers. A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate drug is a promising candidate for COVID-19 patients.

The novel screening approach identified four promising drugs, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus. Further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir, a drug that is currently used to treat some Covid-19 patients, said Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China.

Zhanh and team screened 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP). The findings, published in open-access journal PLOS Computational Biology, suggest that pralatrexate could potentially be repurposed to treat COVID-19. "However, this chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for Covid-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed," the researchers noted.

With the COVID-19 pandemic causing illness and death worldwide, better treatments are urgently needed. One shortcut could be to repurpose existing drugs that were originally developed to treat other conditions. "We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," Zhang said.

He and his colleagues are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat Covid-19.

telegram

O
P
E
N

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
telegram
ADVERTISEMENT
Write to us!

If you have campus news, views, works of art, photos or just want to reach out to us, just drop us a line.

newsletter_icon
Mailbox
edexlive@gmail.com
fb_icon
Facebook
twitter_icon
Twitter
insta_icon
Instagram
ADVERTISEMENT
Facebook
ADVERTISEMENT
Tweets by Xpress_edex
ADVERTISEMENT
ADVERTISEMENT

FOLLOW US

Copyright - edexlive.com 2021

The New Indian Express | Dinamani | Kannada Prabha | Samakalika Malayalam | Indulgexpress | Cinema Express | Event Xpress

Contact Us | About Us | Privacy Policy | Terms of Use | Advertise With Us

Home | Live Now | Live Story | Campus Trip | Coach Calling | Live Take